Literature DB >> 15947895

The role of aldosterone blockade in patients with heart failure.

Bertram Pitt1.   

Abstract

The mechanisms associated with aldosterone production both systemically and locally as well as the effects of aldosterone blockade on the pathophysiology of heart failure (HF) have been extensively reviewed in this series and elsewhere. This article will review the clinical evidence supporting the use of aldosterone blocking agents (AB)in patients with HF and speculate on some potential future uses.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15947895     DOI： 10.1007/s10741-005-2352-2

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN： 1382-4147            Impact factor:   4.214


  21 in total

1.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

2.  Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients.

Authors:  R J MacFadyen; C S Barr; A D Struthers
Journal:  Cardiovasc Res       Date:  1997-07       Impact factor: 10.787

3.  Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment.

Authors:  William R Ravis; Susan Reid; Domenic A Sica; Dwain S Tolbert
Journal:  J Clin Pharmacol       Date:  2005-07       Impact factor: 3.126

4.  Mineralocorticoid receptor antagonism in experimental atherosclerosis.

Authors:  Sanjay Rajagopalan; Damon Duquaine; Steven King; Bertram Pitt; Paresh Patel
Journal:  Circulation       Date:  2002-05-07       Impact factor: 29.690

5.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

6.  Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction.

Authors:  Masaru Hayashi; Takayoshi Tsutamoto; Atsuyuki Wada; Takashi Tsutsui; Chitose Ishii; Keijin Ohno; Masanori Fujii; Atsushi Taniguchi; Tomokazu Hamatani; Yoshitaka Nozato; Ken Kataoka; Naoki Morigami; Masato Ohnishi; Masahiko Kinoshita; Minoru Horie
Journal:  Circulation       Date:  2003-05-05       Impact factor: 29.690

7.  Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure.

Authors:  Philip M Mottram; Brian Haluska; Rodel Leano; Diane Cowley; Michael Stowasser; Thomas H Marwick
Journal:  Circulation       Date:  2004-07-26       Impact factor: 29.690

8.  Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.

Authors:  Daniela Fraccarollo; Paolo Galuppo; Steven Hildemann; Michael Christ; Georg Ertl; Johann Bauersachs
Journal:  J Am Coll Cardiol       Date:  2003-11-05       Impact factor: 24.094

9.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

10.  Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro.

Authors:  M de Gasparo; U Joss; H P Ramjoué; S E Whitebread; H Haenni; L Schenkel; C Kraehenbuehl; M Biollaz; J Grob; J Schmidlin
Journal:  J Pharmacol Exp Ther       Date:  1987-02       Impact factor: 4.030
View more
  1 in total

1.  Mineralocorticoid receptor is essential for corticosteroid-induced up-regulation of L-type calcium currents in cultured neonatal cardiomyocytes.

Authors:  Jean-Sébastien Rougier; Olivier Muller; Stefan Berger; Gabriel Centeno; Günther Schütz; Dmitri Firsov; Hugues Abriel
Journal:  Pflugers Arch       Date:  2007-11-27       Impact factor: 3.657
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.